Targeting a specific protein to prevent leukemia relapse and complications after stem cell transplants
Official title: Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation
Funded at Roswell Park Cancer Institute Corp · NIH-10812513 · Data updated 2026-11-12
This study is looking at a new way to help patients with leukemia who are getting a stem cell transplant by using special T cells that target a protein called CD83, which could help prevent the cancer from coming back and reduce side effects from the transplant.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $640,704 |
| NIH project number | 5R01HL167232-03 |
| Project ID | NIH-10812513 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with acute leukemia who are scheduled to undergo allogeneic hematopoietic cell transplantation.
✕Less likely to help
Patients who do not have acute leukemia or those who are not candidates for stem cell transplantation may not benefit from this research.
What this research studies
This research focuses on improving outcomes for patients undergoing allogeneic hematopoietic cell transplantation by targeting CD83, a protein involved in immune responses. The approach involves using engineered T cells that specifically attack leukemia cells expressing CD83 while minimizing damage to healthy cells. By doing so, the research aims to reduce the risk of both leukemia relapse and graft-versus-host disease (GVHD), a common complication after transplantation. The study will assess the effectiveness of these CD83-targeted T cells in preventing disease recurrence and improving patient survival rates.
Why it matters
Potential benefit: If successful, this research could significantly enhance the survival rates and quality of life for patients undergoing stem cell transplants by reducing the chances of leukemia returning and minimizing harmful side effects.
How similar studies have gone: Previous research has shown promising results with similar targeted therapies in reducing complications and improving outcomes in leukemia treatment, indicating potential for success in this novel approach.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Betts, Brian C — Roswell Park Cancer Institute Corp
- Study coordinator: Betts, Brian C
Related research
Other NIH-funded projects on the same topics.
-
Targeting VLDLR to prevent both GvHD and leukemia relapse
A new approach using the VLDLR target aims to prevent graft-versus-host disease while keeping the anti-leukemia effects after allogeneic stem cell transplantation.
-
Reducing leukemia relapse and graft-versus-host disease after donor stem-cell transplant by targeting CD83
This work uses engineered immune cells that target a protein called CD83 to try to prevent relapse of acute leukemias and reduce graft-versus-host disease in people receiving donor stem-cell transplants.
-
Genes that make leukemia stem cells grow and cause AML to come back
This project looks at which genes help leukemia stem cells survive treatment and cause AML to return in adults.
-
Understanding genes that affect stem cell growth and relapse in Acute Myeloid Leukemia
This study is looking at how certain genes affect the growth of blood cells in people with Acute Myeloid Leukemia (AML) to understand why some patients might experience a return of the disease after treatment, with the hope of finding better ways to help them.
-
Predicting relapse in children diagnosed with acute lymphoblastic leukemia
This study is looking to help doctors better predict if children with acute lymphoblastic leukemia might have a relapse by finding certain cells in their blood right at the time of diagnosis, so they can adjust treatments and improve outcomes for these kids.
-
Improving outcomes for children and young adults with relapsed B-cell leukemia after CAR T-cell therapy
This study is looking for ways to help children and young adults with B-cell acute lymphoblastic leukemia who have had a relapse after a specific type of treatment, by testing new treatment strategies and better ways to track their health at the Children's Hospital of Philadelphia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.